Composition containing artemisinin derivatives and use thereof in preparing leukemia treatment drugs

Noxa is induced by artesunate, and the induction of apoptosis in conjunction with venetoclax and reduce Mcl-1 protein, the drug resistance problem caused by the feedback upregulation of anti-apoptotic proteins in AML treatment was solved, and the killing effect on AML cells was significantly improved.

CN116531395BActive Publication Date: 2024-11-05SHENYANG PHARMA UNIV
View PDF 8 Cites 0 Cited by

Patent Information

Application Number
CN202210085636.5
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2022-01-25
Publication Date
2024-11-05
Estimated Expiration
2042-01-25

AI Technical Summary

Technical Problem

The existing treatment methods for acute myeloid leukemia (AML) are subject to drug resistance due to feedback upregulation of anti-apoptotic proteins. The therapeutic effect of the combined regimen of venetoclax and cytarabine is limited and needs improvement.

Method used

Using a composition of artesunate, venetoclax and cytarabine, artesunate synergistically induces apoptosis by inducing Noxa, reducing Mcl-1 protein levels, and overcoming Mcl-1-mediated cytarabine tolerance , enhances the DNA damage effect induced by cytarabine, and three pharmaceutical compositions can induce apoptosis and DNA damage in acute myeloid leukemia cells.

Benefits of technology

The therapeutic effect of venetoclax and cytarabine combined regimen on AML was significantly improved, the killing effect on AML cells was enhanced, and drug resistance caused by feedback upregulation of anti-apoptotic proteins was overcome.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN116531395B_ABST
    Figure CN116531395B_ABST
Patent Text Reader

Abstract

The present invention belongs to the field of biomedicine, and specifically relates to a composition containing artemisinin derivatives and its application in the preparation of a drug for treating leukemia. The composition of the present invention is a mixture of component A, component B and component C in a ratio of 8-40:1-2:1-80; wherein component A is one or more of artesunate and its analogs; the analogs may be artemisinin, dihydroartemisinin, artemether, arteether, etc.; component B is one or more of venetoclax and its analogs; the analogs may be navitoclax, etc.; component C is one or more of cytarabine and its analogs; the analogs may be azacitidine, decitabine, gemcitabine, etc.; the present invention overcomes the drug resistance caused by the feedback upregulation of other anti-apoptotic proteins in the prior art artesunate and cytarabine combination scheme and venetoclax and cytarabine combination scheme, and significantly improves the therapeutic effect of the venetoclax and cytarabine combination scheme on AML.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of biomedicine, and specifically relates to a pharmaceutical composition containing artesunate, venetoclax and cytarabine, and an application of the pharmaceutical composition in preparing a drug for treating acute myeloid leukemia. Background Art

[0002] Acute myeloid leukemia (AML) is one of the most aggressive hematological malignancies. Elderly AML patients are mainly treated with hypomethylating drugs (HMAS) or low-dose cytarabine (LDAC), and the prognosis of patients is extremely poor, with a 5-year overall survival rate of no more than 10%. Young AML patients have been treated with the "7+3" (daunorubicin + cytarabine) induction regimen from 40 years ago. The remission rate of this treatment regimen is between 30-80%, but due to relapse, the long-term survival rate and cure rate are low, and the treatment effect needs to be improved.

[0003] Apoptosis arrest is a common feature of AML. Abnormal expression of anti-apoptotic proteins Bcl-2 and Mcl-1 increases the apoptosis threshold of AML cells and is one of the main causes of AML onset and drug resistance. Venetoclax is currently the only small molecule inhibitor of Bcl-2 family anti-apoptotic proteins approved for the treatment of CLL and AML, but its effect in AML is limited when used alone. Clinical studies have found that venetoclax improves the therapeutic effect of azacitidine, decitabine or low-dose cytarabine on AML. This combination regimen was approved in 2018 for the treatment of elderly AML patients who are not suitable for intensive treatment. However, compared with cytarabine alone, the median survival of patients with this combination regimen was only extended by 4 months. Ultimately, the treatment failed due to the emergence of drug resistance, and the treatment effect still needs to be further improved.

[0004] The anti-apoptotic protein Mcl-1 is considered to be the main cause of venetoclax tolerance. Venetoclax induces cell apoptosis by inhibiting the release of Bim from Bcl-2, but the released Bim is seized by Mcl-1, leading to venetoclax tolerance. Mcl-1 can also transfer to the nucleus and bind to chromatin to reduce DNA damage, and induce p-Chk1 to initiate DNA damage repair. Mcl-1 is also involved in the tolerance process of cytarabine. Targeted inhibition of Mcl-1 is expected to improve the therapeutic effect of venetoclax combined with cytarabine on AML. The intracellular Mcl-1 protein level is regulated by Noxa and Bim. Noxa can displace Bim in Mcl-1 and induce Mcl-1 degradation, suggesting that drugs that induce Noxa may target and inhibit Mcl-1 by reducing the protein level of Mcl-1, thereby enhancing the therapeutic effect of venetoclax combined with cytarabine.

[0005] At present, Chinese researchers have summarized the combination of artesunate and cytarabine, and the combination of venetoclax and cytarabine has been clinically approved. However, both of these regimens have limited therapeutic effects on AML due to drug resistance caused by the feedback upregulation of other anti-apoptotic proteins. Summary of the invention

[0006] In order to overcome the existing technical defects, the present invention provides a pharmaceutical composition containing artesunate, venetoclax and cytarabine and its use in the preparation of drugs for treating acute myeloid leukemia. Further, artesunate in the composition induces Noxa, synergistically induces apoptosis with venetoclax, reduces Mcl-1 protein, overcomes Mcl-1-mediated cytarabine tolerance, and enhances cytarabine-induced DNA damage. The three pharmaceutical compositions can induce apoptosis and DNA damage in acute myeloid leukemia cells, and improve the current status of the combined treatment of venetoclax and cytarabine for AML.

[0007] To achieve the above purpose, the present invention adopts the following technical solution:

[0008] A composition containing artemisinin derivatives, wherein the composition comprises component A, component B and component C mixed in a ratio of 8-40:1-2:1-80; wherein:

[0009] The component A is one or more of artesunate and its analogs; the analogs may be artemisinin, dihydroartemisinin, artemether, arteether, etc.;

[0010] The B component is one or more of venetoclax and its analogs; the analogs may be navitoclax, etc.;

[0011] The C component is one or more of cytarabine and its analogs; the analogs may be azacitidine, decitabine, gemcitabine, etc.;

[0012] Preferably, the component A is artesunate; the component B is venetoclax; and the component C is cytarabine.

[0013] The structural formula of artesunate is shown in Ⅰ.

[0014]

[0015] The Bcl-2 inhibitor venetoclax is a compound represented by formula II:

[0016]

[0017] Cytarabine is a compound represented by formula III:

[0018]

[0019] An application of a composition containing artemisinin derivatives, and application of the composition in the preparation of a drug for treating blood tumors including leukemia and lymphoma.

[0020] The composition is used in preparing a drug for treating acute myeloid leukemia by inducing leukemia cell apoptosis and DNA damage in a coordinated manner.

[0021] The acute myeloid leukemia cells are THP-1 or MOLM-13 cells.

[0022] When preparing the drug for treating THP-1, the components A, B and C of the composition are mixed in a ratio of 8:1:5;

[0023] When preparing the drug for treating MOLM-13, component A, component B and component C of the composition are mixed in a ratio of 40:2:1.

[0024] A preparation of a composition containing artemisinin derivatives, wherein the active ingredient of the preparation is mixed with a pharmaceutically acceptable carrier, wherein the active ingredient is the composition according to claim 1, and the active ingredient accounts for 0.01-99% of the preparation mass.

[0025] The preparation is in the form of tablets, capsules and granules.

[0026] The preparation is prepared by mixing the components in the composition and then mixing them with a pharmaceutically acceptable carrier, or by separately preparing the components in the composition with a pharmaceutically acceptable carrier and then mixing them.

[0027] Furthermore, in the scheme of preparing the composition of the present invention into a medicament for simultaneous administration, artesunate, the Bcl-2 inhibitor venetoclax and cytarabine can be contained in the same pharmaceutical preparation such as tablets or capsules, and the patient takes it according to the instructions of the instructions, or the three components in the above-mentioned composition are prepared into a controlled-release preparation, and the components in the composition are released sequentially, and the patient only needs to take the controlled-release composition preparation; in the scheme of preparing the composition of the present invention into a preparation for cross-administration, artesunate, the Bcl-2 inhibitor venetoclax and cytarabine can be made into different preparations respectively, and they can be packaged or combined together in a conventional manner in the art, and then the patient takes it in the cross-order indicated in the drug instructions, or the pharmaceutical composition is prepared into a controlled-release preparation with cross-release of artesunate, the Bcl-2 inhibitor venetoclax and cytarabine.

[0028] The advantages of the present invention are:

[0029] The present invention provides a composition of artesunate, Bcl-2 inhibitor venetoclax and cytarabine, and explains in terms of mechanism that artesunate can induce cell apoptosis by inducing Noxa and cooperating with venetoclax to overcome venetoclax tolerance, while downregulating Mcl-1 protein, overcoming the p-Chk1 feedback activation and DNA damage repair process induced by cytarabine, and enhancing the killing effect of cytarabine on leukemia cells. The present invention overcomes the drug resistance caused by the feedback upregulation of other anti-apoptotic proteins in the prior art combination of artesunate and cytarabine and the combination of venetoclax and cytarabine, and significantly improves the therapeutic effect of the combination of venetoclax and cytarabine on AML. BRIEF DESCRIPTION OF THE DRAWINGS

[0030] Figure 1 This is a graph showing the growth inhibition effect of the composition of the present invention on AML cells in THP-1 and MOLM-13 cells provided in an embodiment of the present invention;

[0031] Figure 2 This is a graph showing the effect of the composition of the present invention on inducing apoptosis of AML cells in THP-1 and MOLM-13 cells, provided in an embodiment of the present invention;

[0032] Figure 3 This is a diagram showing the killing effect of the composition of the present invention on AML cells in THP-1 and MOLM-13 cells provided in the embodiments of the present invention;

[0033] Figure 4 The present invention provides an example of the present invention, which shows the effect of using the composition of the present invention to inhibit colony formation in THP-1 and MOLM-13 cells.

[0034] Figure 5 The present invention provides an embodiment of the present invention, wherein A is a picture of the mouse tumor, B is the mouse tumor weight, and C is the mouse body weight.

[0035] Figure 6 This is a graph showing the use of the composition of the present invention in NOD-SCID mice to extend the survival of xenografted mice, as provided in an embodiment of the present invention.

[0036] Figure 7 The present invention provides an example of using the composition of the present invention to investigate the effects of inducing pro-apoptotic Noxa, down-regulating anti-apoptotic Mcl-1, inhibiting replication stress checkpoint kinase p-Chk1, and inducing DNA damage protein □-H2A.X protein in THP-1 and MOLM-13 cells. . DETAILED DESCRIPTION

[0037] The essential contents of the present invention are further illustrated below in conjunction with the embodiments, but the protection scope of the present invention is not limited thereto.

[0038] The cells and drugs used in the examples of this application are as follows:

[0039] Cells: Human acute myeloid leukemia THP-1 cells were purchased from American Type Culture Collection (ATCC). Human acute myeloid leukemia Molm-13 cells were purchased from DSMZ-Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH (Braunschweig Germany). Drugs: The pharmaceutical compositions used in the following examples were prepared according to the following methods; artesunate was purchased from Sigma, with a storage concentration of 10 mM; venetoclax was purchased from Selleck, with a storage concentration of 10 mM; cytarabine was purchased from MedChemExpress, with a storage concentration of 20 mM.

[0040] Example 1

[0041] Reagents and methods:

[0042] Accurately weigh artesunate and ABT-199, dissolve them in dimethyl sulfoxide, prepare 10mM stock solutions, store them at -20℃, and dilute them with ethanol to the appropriate concentration when using. Accurately weigh cytarabine, dissolve it in PBS filtered by 0.22μm filter membrane; then dilute artesunate, venetoclax and cytarabine to the appropriate concentration with fresh culture medium (1640 culture medium) when using. In all experiments, the final concentrations of dimethyl sulfoxide and ethanol were strictly controlled, the final concentration of dimethyl sulfoxide did not exceed 1‰, and the final concentration of ethanol did not exceed 1%, which did not affect cell activity.

[0043] THP-1 cells and Molm-13 cells were cultured in 1640 medium containing 10% inactivated fetal bovine serum, 10 mmol / L L-glutamine, 100 U / mL penicillin, and 100 μg / mL streptomycin at 37°C and 5% CO2 saturated humidity.

[0044] Cells in logarithmic growth phase were divided into 5 The cells were inoculated at a density of 1:1 in a 24-well plate and treated with different drug concentrations (see Table 1-6). After 72 hours, dead cells were observed by trypan blue staining. The mixed cells were mixed with trypan blue dye at a ratio of 1:1 (v / v). After staining, normal cells and blue-stained dead cells were counted using an optical microscope and a hemocytometer (see Figure 1The cell growth inhibition rate (GI) was calculated according to the following formula, and the half growth inhibition concentration (GI 50 : Drug concentration that makes cell growth inhibition rate reach 50%).

[0045] GI = (number of cells in control well - number of cells in drug-added well) / number of cells in control well × 100%

[0046] The synergy index (CI) of the drug combination was calculated using Compusyn software.

[0047] Table 1 Synergistic inhibition of THP-1 cell growth by combination of different concentrations of artesunate and venetoclax

[0048] Artesunate (μM) Venetoclax (μM) Growth inhibition rate (%) Combined Index CI 0.2 -- 10.29 -- 0.4 -- 17.65 -- 0.8 -- 31.80 -- -- 0.1 15.51 -- -- 0.5 22.96 -- -- 1 40.82 -- 0.2 0.1 35.52 0.47 0.2 0.5 49.58 0.58 0.2 1 78.82 0.49 0.4 0.1 42.02 0.34 0.4 0.5 55.83 0.39 0.4 1 85.41 0.42 0.8 0.1 59.13 0.12 0.8 0.5 64.83 0.10 0.8 1 88.14 0.11

[0049] As can be seen from Table 1, acute myeloid leukemia cell line THP-1 cells were treated with artesunate 0.2-0.8μM and venetoclax 0.1-1μM for 72h. When artesunate and venetoclax were used alone, the cell growth inhibition ratio was <50%. The addition of artesunate significantly enhanced the cell growth inhibition effect of venetoclax. The combination index of the two drugs was calculated using Compusyn software. A combination index of >1 indicates that the two compounds are antagonistic, and <1 indicates a synergistic effect. The combination index of artesunate and venetoclax is <0.6, indicating that the two compounds have a synergistic effect. The combination of 0.8μM artesunate and 0.1μM venetoclax inhibited the growth of THP-1 cells by 59%, CI = 0.12, showing a strong synergistic cell growth inhibition effect.

[0050] Table 2 Synergistic inhibition of MOLM-13 cell growth by combination of different concentrations of artesunate and venetoclax

[0051] Artesunate (μM) Venetoclax (μM) Growth inhibition rate (%) Combined Index CI 0.1 -- 7.89 -- 0.2 -- 13.61 -- 0.4 -- 27.83 -- -- 0.0025 29.57 -- -- 0.005 36.02 -- -- 0.01 45.02 -- 0.1 0.0025 60.6 0.11 0.1 0.005 62.06 0.11 0.1 0.01 66.79 0.08 0.2 0.0025 66.49 0.15 0.2 0.005 69.9 0.13 0.2 0.01 74.24 0.08 0.4 0.0025 73.99 0.18 0.4 0.005 78.11 0.15 0.4 0.01 84.03 0.07

[0052] As shown in Table 2, acute myeloid leukemia cell line MOLM-13 cells are more sensitive to artesunate and venetoclax than THP-1 cells. Artesunate 0.1-0.4μM, combined with venetoclax 0.0025-0.01μM, was treated for 72h. When artesunate and venetoclax were used alone, the cell growth inhibition ratio was <50%. The addition of artesunate significantly enhanced the cell growth inhibition effect of venetoclax. The combination index of the two drugs was calculated using Compusyn software. The combination index of artesunate and venetoclax was <0.2, indicating that the two compounds had a very strong synergistic effect. The combined application of 0.2μM artesunate and 0.01μM venetoclax inhibited the growth of MOLM-13 cells by 74%, CI = 0.08, showing a strong synergistic cell growth inhibition effect.

[0053] According to experimental findings, artesunate and venetoclax synergistically kill AML cells by inducing cell apoptosis, but their effects are limited at the in vivo animal experiment level, so there is a need to find new combination regimens.

[0054] Table 3 Experiment on the combined inhibition of THP-1 cell growth by different concentrations of artesunate and cytarabine

[0055]

[0056]

[0057] As shown in Table 3, THP-1 cells were treated with artesunate 0.2-0.8μM and cytarabine 0.25-1μM for 72h. When artesunate and cytarabine were used alone, the cell growth inhibition ratio was <50%. Artesunate could not significantly enhance the cell growth inhibition effect of cytarabine. The combination index of the two drugs was calculated by Compusyn software. The combination index was >1, indicating that the two compounds had an antagonistic effect. 0.8μM artesunate was combined with 0.5μM venetoclax to inhibit THP-1 cell growth by 49%, CI = 1.23, showing an antagonistic effect.

[0058] Table 4 Experiment on the combined inhibition of MOLM-13 cell growth by different concentrations of artesunate and cytarabine

[0059] Artesunate (μM) Cytarabine (μM) Growth inhibition rate (%) Combined Index CI 0.1 -- 21.73 -- 0.2 -- 35.35 -- 0.4 -- 46.44 -- -- 0.00125 3.74 -- -- 0.0025 7.36 -- -- 0.005 13.94 -- 0.1 0.00125 17.24 1.75 0.1 0.0025 26.97 0.95 0.1 0.005 24.81 1.31 0.2 0.00125 37.64 0.84 0.2 0.0025 40.47 0.82 0.2 0.005 44.68 0.73 0.4 0.00125 48.17 0.98 0.4 0.0025 50.94 0.88

[0060] As shown in Table 4, MOLM-13 cells were treated with artesunate 0.1-0.4μM and cytarabine 0.00125-0.005μM for 72h. When artesunate and cytarabine were used alone, the cell growth inhibition ratio was <50%. Artesunate could not significantly enhance the cell growth inhibition effect of cytarabine. The combination index of the two drugs was calculated by Compusyn software. The combination index was >0.7, and the synergistic index was >1 at some doses, indicating that the two compounds had no obvious synergistic effect. The combination of 0.2μM artesunate and 0.005μM cytarabine inhibited the growth of THP-1 cells by 45%, CI = 0.73, showing a weak synergistic cell growth inhibition effect.

[0061] The above experimental data indicate that artesunate and cytarabine cannot exert obvious synergistic effects at the AML cell level.

[0062] Table 5 Synergistic inhibition of THP-1 cell growth by the combination of different concentrations of venetoclax and cytarabine

[0063] Venetoclax (μM) Cytarabine (μM) Growth inhibition rate (%) Combined Index CI 0.1 -- 8.52 -- 0.5 -- 20.81 -- 1 -- 29.66 -- -- 0.25 19.84 -- -- 0.5 29.99 -- -- 1 43.5 -- 0.1 0.25 37.61 0.51 0.1 0.5 49.82 0.52 0.1 1 61.22 0.49 0.5 0.25 43.18 0.57 0.5 0.5 53.25 0.53 0.5 1 67.52 0.41 1 0.25 52.43 0.63 1 0.5 59.68 0.56 1 1 72.68 0.41

[0064] As can be seen from Table 5, THP-1 cells were treated with venetoclax 0.1-1μM and cytarabine 0.25-1μM for 72h. When venetoclax and cytarabine were used alone, the cell growth inhibition ratio was <50%. The addition of venetoclax can significantly enhance the cell growth inhibition effect of cytarabine. The combination index of the two drugs was calculated using Compusyn software, and the combination index was <0.6, indicating that the two compounds have a synergistic cell growth inhibition effect. The combination of 0.1μM venetoclax and 0.5μM cytarabine inhibited THP-1 cell growth by 50%, CI = 0.52, showing a synergistic cell growth inhibition effect.

[0065] Table 6 Synergistic inhibition of MOLM-13 cell growth by the combination of different concentrations of venetoclax and cytarabine

[0066] Venetoclax (μM) Cytarabine (μM) Growth inhibition rate (%) Combined Index CI 0.0025 -- 20.27 -- 0.005 -- 26.35 -- 0.01 -- 35.98 -- -- 0.00125 9.2 -- -- 0.0025 11.28 -- -- 0.005 22.3 -- 0.0025 0.00125 43.63 0.2 0.0025 0.0025 56.27 0.13 0.0025 0.005 60.96 0.15 0.005 0.00125 48.8 0.24 0.005 0.0025 61.88 0.13 0.005 0.005 67.83 0.12 0.01 0.00125 62.64 0.17 0.01 0.0025 71.64 0.1 0.01 0.005 79.11 0.07

[0067] As can be seen from Table 6, MOLM-13 cells were treated with venetoclax 0.0025-0.01μM and cytarabine 0.00125-0.005μM for 72h. When venetoclax and cytarabine were used alone, the cell growth inhibition ratio was <50%. The addition of venetoclax can significantly enhance the cell growth inhibition effect of cytarabine. The combination index of the two drugs was calculated using Compusyn software, and the combination index was <0.3, indicating that the two compounds have a strong synergistic effect of inhibiting cell growth. The combination of 0.01μM venetoclax and 0.005μM cytarabine inhibited the growth of THP-1 cells by 79%, CI = 0.07, showing a strong synergistic cell growth inhibition effect.

[0068] Although the combination of cytarabine and venetoclax has been approved for the treatment of elderly AML patients, its clinical therapeutic effect is limited, so there is still a need to find new combination regimens.

[0069] In two AML cell lines, the combination of artesunate and venetoclax and venetoclax and cytarabine can synergistically inhibit the growth of AML cells, while the combination of artesunate and cytarabine cannot exert obvious synergistic effects. Based on the above experiments, artesunate, venetoclax and cytarabine were further combined at three drug concentrations to examine the killing effect on AML cells.

[0070] Then, experimental groups were set up according to the effects of the above substances alone and in combination, and the growth inhibition of AML cells was tested in the above manner, see Figure 1 .

[0071] The experimental groups for THP-1 cells are as follows: (1) blank control group; (2) artesunate group (0.8 μM); (3) venetoclax group (0.1 μM); (4) cytarabine group (0.5 μM); (5) artesunate (0.8 μM) + venetoclax (0.1 μM) group; (6) artesunate (0.8 μM) + cytarabine (0.5 μM) group; (7) venetoclax (0.1 μM) + cytarabine (0.5 μM) group; (8) artesunate (0.8 μM) + venetoclax (0.1 μM) + cytarabine (0.5 μM) group.

[0072] The experimental groups for MOLM-13 cells are as follows: (1) blank control group; (2) artesunate group (0.2 μM); (3) venetoclax group (0.01 μM); (4) cytarabine group (0.005 μM); (5) artesunate (0.2 μM) + venetoclax (0.01 μM) group; (6) artesunate (0.2 μM) + cytarabine (0.005 μM) group; (7) venetoclax (0.01 μM) + cytarabine (0.005 μM) group; (8) artesunate (0.2 μM) + venetoclax (0.01 μM) + cytarabine (0.005 μM) group.

[0073] Depend on Figure 1 It can be seen that in THP-1 cells, different experimental groups had an inhibitory effect on the growth of AML cells. The artesunate + venetoclax group and the venetoclax + cytarabine group could inhibit 70% and 59% of cell growth, respectively, which were better than any single drug group (artesunate 25%, venetoclax 31%, cytarabine 38%). The combination of artesunate and cytarabine inhibited 44% of cell growth, without significantly enhancing the growth inhibitory effect of cytarabine or artesunate. The artesunate + venetoclax + cytarabine group could inhibit 85% of cell growth, which was better than any combination of the two drugs.

[0074] Since MOLM-13 cells are more sensitive to artesunate, venetoclax and cytarabine than THP-1 cells, the effects of each group are artesunate + venetoclax group and venetoclax + cytarabine group, which can inhibit 71% and 70% of cell growth, respectively, and the activity is better than any single drug group (artesunate 17%, venetoclax 38%, cytarabine 26%). Artesunate combined with cytarabine inhibits 35% of cell growth, and does not significantly enhance the growth inhibitory effect of cytarabine or artesunate. Artesunate + venetoclax + cytarabine group can inhibit 92% of cell growth, and the activity is better than any two-drug combination group. It suggests that artesunate can significantly enhance the growth inhibitory effect of venetoclax and cytarabine combination on AML cells.

[0075] Example 2

[0076] THP-1 cells and Molm-13 cells in the logarithmic growth phase were taken and 5The cells were seeded at different densities in 6-well plates, and then different drugs were added to different THP-1 and MOLM-13 cells for treatment alone or in combination for 24 h or 12 h. The THP-1 cell experimental groups were as follows: (1) blank control group; (2) artesunate group (0.8 μM); (3) venetoclax group (0.1 μM); (4) cytarabine group (8 μM); (5) artesunate (0.8 μM) + venetoclax (0.1 μM) group; (6) artesunate (0.8 μM) + cytarabine (8 μM) group; (7) venetoclax (0.1 μM) + cytarabine (8 μM) group; (8) artesunate (0.8 μM) + venetoclax (0.1 μM) + cytarabine (8 μM) group.

[0077] The MOLM-13 cell experimental groups are as follows: (1) blank control group; (2) artesunate group (0.2 μM); (3) venetoclax group (0.01 μM); (4) cytarabine group (0.08 μM); (5) artesunate (0.2 μM) + venetoclax (0.01 μM) group; (6) artesunate (0.2 μM) + cytarabine (0.08 μM) group; (7) venetoclax (0.01 μM) + cytarabine (0.08 μM) group; (8) artesunate (0.2 μM) + venetoclax (0.01 μM) + cytarabine (0.08 μM) group. Cell apoptosis was detected using the AV-PI kit (see Figure 2 );

[0078] The results are shown in the figure. In THP-1 cells, the artesunate + venetoclax group can induce 28% of cells to undergo apoptosis, and its activity is better than any single drug group (artesunate 4%, venetoclax 5%). Artesunate + cytarabine (8%) and venetoclax + cytarabine groups (9%) cannot significantly induce cell apoptosis. Artesunate + venetoclax + cytarabine group can induce 38% of cells to undergo apoptosis, and its activity is better than any combination of the two drugs. In MOLM-13 cells, venetoclax alone can induce apoptosis in 25% of cells, and the apoptosis rate increased to 43% or 45% when combined with artesunate or cytarabine, which is better than any single drug group (artesunate 11%, venetoclax 25%, cytarabine 14%). Artesunate combined with cytarabine can induce apoptosis in 15% of cells, without significantly enhancing the apoptosis-inducing effect of cytarabine or artesunate. Artesunate + venetoclax + cytarabine group can induce apoptosis in 59% of cells, which is better than any two-drug combination group. This suggests that artesunate can significantly enhance the apoptosis-inducing effect of venetoclax and cytarabine combination on AML cells.

[0079] Example 3

[0080] THP-1 cells and Molm-13 cells in the logarithmic growth phase were taken and 5 The cells were seeded in 6-well plates at different densities, and different drugs were added to THP-1 and MOLM-13 cells for treatment alone or in combination for 24 h or 12 h. The THP-1 cells were divided into the following experimental groups: (1) blank control group; (2) artesunate group (0.8 μM); (3) venetoclax group (0.1 μM); (4) cytarabine group (8 μM); (5) artesunate (0.8 μM) + venetoclax (0.1 μM) group; (6) artesunate (0.8 μM) + cytarabine (8 μM) group; (7) venetoclax (0.1 μM) + cytarabine (8 μM) group; (8) artesunate (0.8 μM) + venetoclax (0.1 μM) + cytarabine (8 μM) group.

[0081] The MOLM-13 cell experimental groups are as follows: (1) blank control group; (2) artesunate group (0.2μM); (3) venetoclax group (0.01μM); (4) cytarabine group (0.08μM); (5) artesunate (0.2μM) + venetoclax (0.01μM) group; (6) artesunate (0.2μM) + cytarabine (0.08μM) group; (7) venetoclax (0.01μM) + cytarabine (0.08μM) group; (8) artesunate (0.2μM) + venetoclax (0.01μM) + cytarabine (0.08μM) group. PI single staining method was used to detect cell cycle changes (see Figure 3 ).

[0082] The results are shown in the figure. In THP-1 cells, the artesunate + venetoclax group and the venetoclax + cytarabine group can induce an increase of 26% and 19% of Sub-G1 phase cells, and the activity is better than any single drug group (artesunate 4%, venetoclax 4%, cytarabine 8%). The artesunate + cytarabine group cannot significantly induce an increase in the proportion of Sub-G1 phase cells. The artesunate + venetoclax + cytarabine group can induce an increase of 32% of Sub-G1 phase cells, and the activity is better than any two-drug combination group. In MOLM-13 cells, venetoclax alone can induce a 33% increase in the proportion of Sub-G1 cells, and combined with artesunate and cytarabine, the proportion of Sub-G1 cells increased to 45% and 40%, which is better than any single drug group (artesunate 9%, venetoclax 33%, cytarabine 11%). Artesunate combined with cytarabine can induce a 14% increase in the proportion of Sub-G1 cells, without significantly enhancing the effect of cytarabine or artesunate. The artesunate + venetoclax + cytarabine group can induce a 51% increase in the proportion of Sub-G1 cells, which is better than any two-drug combination group. This suggests that artesunate can significantly enhance the effect of venetoclax combined with cytarabine on inducing DNA breaks in AML cells. The above results confirm that artesunate can significantly enhance the killing effect of venetoclax combined with cytarabine on AML cells.

[0083] Example 4

[0084] The effect on the proliferation potential of single cells was investigated using soft agar colony formation assay in THP-1 and MOLM-13 cells.

[0085] Take 20 μL of the test drug and mix it into the soft agar bottom layer. Take 5000 THP-1 cells and Molm-13 cells in the logarithmic growth phase and mix them into the soft agar upper layer. After 14 days, count the colonies with a diameter greater than 75 μm (more than 50 cells) under a dissection microscope (see Figure 4 ).

[0086] The THP-1 cell experimental groups were as follows: (1) blank control group; (2) artesunate group (0.8 μM); (3) venetoclax group (0.1 μM); (4) cytarabine group (0.5 μM); (5) artesunate (0.8 μM) + venetoclax (0.1 μM) group; (6) artesunate (0.8 μM) + cytarabine (0.5 μM) group; (7) venetoclax (0.1 μM) + cytarabine (0.5 μM) group; (8) artesunate (0.8 μM) + venetoclax (0.1 μM) + cytarabine (0.5 μM) group.

[0087] The MOLM-13 cell experimental groups were as follows: (1) blank control group; (2) artesunate group (0.2 μM); (3) venetoclax group (0.01 μM); (4) cytarabine group (0.005 μM); (5) artesunate (0.2 μM) + venetoclax (0.01 μM) group; (6) artesunate (0.2 μM) + cytarabine (0.005 μM) group; (7) venetoclax (0.01 μM) + cytarabine (0.005 μM) group; (8) artesunate (0.2 μM) + venetoclax (0.01 μM) + cytarabine (0.005 μM) group. The experimental results are shown in the figure. Artesunate alone cannot inhibit colony formation; Venetoclax and cytarabine alone inhibit no more than 30% of colony formation, and the inhibitory effect is limited; the artesunate + venetoclax group and the venetoclax + cytarabine group inhibited about 70% of colony formation, which was better than any single drug group; artesunate combined with cytarabine inhibited about 50% of colony formation, and did not significantly enhance the inhibitory effect of cytarabine on colony formation; artesunate + venetoclax + cytarabine group inhibited about 90% of colony formation, which was better than any two-drug combination group.

[0088] Example 5

[0089] To investigate the in vivo anti-AML effect of artesunate in combination with venetoclax and cytarabine:

[0090] 40 female NOD-SCID mice were inoculated subcutaneously with 5×10 MOLM-13 cells in the right axilla. 6 When the tumor volume reaches 100mm 2The mice were randomly divided into 8 groups: (1) blank control group; (2) artesunate group (100 mg / kg); (3) venetoclax group (100 mg / kg); (4) cytarabine group (50 mg / kg); (5) artesunate (100 mg / kg) + venetoclax (100 mg / kg) group; (6) artesunate (100 mg / kg) + cytarabine (50 mg / kg) group; (7) venetoclax (100 mg / kg) + cytarabine (50 mg / kg) group; (8) artesunate (100 mg / kg) + venetoclax (100 mg / kg) + cytarabine (50 mg / kg) group. Artesunate is dissolved in 10% (5% NaHCO3) + 90% saline and administered by intraperitoneal injection once a day for 10 consecutive days; Venetoclax is dissolved in 10% ethanol + 30% PEG 400 + 60% Phosal 50PG and administered orally once a day for 10 consecutive days; cytarabine is dissolved in saline and administered by intraperitoneal injection once a day for 10 consecutive days.

[0091] Depend on Figure 5 It can be seen that the tumor inhibition effect of the artesunate group was relatively weak, with a tumor inhibition rate of 22.9%. Venetoclax and cytarabine can effectively inhibit tumor growth, with tumor inhibition rates of 64.2% and 44.8%, respectively. The tumor inhibition rate of the artesunate + cytarabine group was 44.8%, which was the same as that of the cytarabine group, indicating that artesunate could not enhance the tumor inhibition effect of cytarabine. The tumor inhibition rates of the artesunate + venetoclax group and the venetoclax + cytarabine group were 68.2% and 75%, respectively, and neither significantly enhanced the tumor inhibition effect of venetoclax. The tumor inhibition rate of the artesunate + venetoclax + cytarabine group was 92%, and the tumor inhibition effect was better than that of any two-drug combination group. The body weight of mice in the artesunate + venetoclax + cytarabine group did not change significantly during the experiment.

[0092] Example 6

[0093] To simulate the real AML model, 35 female NOD-SCID mice were inoculated with 2×10 MOLM-13 cells via the tail vein. 6Three days later, the mice were randomly divided into 5 groups according to their body weight, namely (1) blank control group; (2) venetoclax (100 mg / kg) group; (3) artesunate (100 mg / kg) + venetoclax (100 mg / kg) group; (4) venetoclax (100 mg / kg) + cytarabine (50 mg / kg) group; (5) artesunate (100 mg / kg) + venetoclax (100 mg / kg) + cytarabine (50 mg / kg) group. Artesunate was dissolved in 10% (5% NaHCO3) + 90% saline and intraperitoneally injected; venetoclax was dissolved in 10% ethanol + 30% PEG 400 + 60% Phosal50PG and orally administered; cytarabine was dissolved in saline and intraperitoneally injected. Artesunate and venetoclax were administered 5 days a week for 4 consecutive weeks; cytarabine was administered for 7 consecutive days. The body weight and survival time of the mice were recorded, and the survival curve of the mice was drawn using the Kaplan-Meier method. The THP-1 cell xenograft model and administration regimen were the same as those of the MOLM-13 cells (see Figure 6 ).

[0094] Depend on Figure 6 It can be seen that the venetoclax group, artesunate + venetoclax group, venetoclax + cytarabine group and artesunate + venetoclax + cytarabine group significantly prolonged the survival of xenotransplanted mice compared with the control group, and the survival of the artesunate + venetoclax + cytarabine group was further prolonged compared with the venetoclax group, artesunate + venetoclax group and venetoclax + cytarabine group, with an ILS% of 118.8%. In the tail vein xenograft THP-1 cell model, the artesunate + venetoclax group, venetoclax + cytarabine group, and artesunate + venetoclax + cytarabine group significantly prolonged the survival of xenograft mice compared with the control group. The artesunate + venetoclax + cytarabine group had a further prolonged survival compared with the venetoclax group, artesunate + venetoclax group, and venetoclax + cytarabine group, with an ILS% of 45.1%. The above results confirm that artesunate can effectively enhance the anti-AML effect of the venetoclax and cytarabine combination regimen in vivo.

[0095] Example 7

[0096] THP-1 cells and Molm-13 cells in the logarithmic growth phase were taken and 5The cells were seeded in 6-well plates at different densities, and different drugs were added to THP-1 and MOLM-13 cells for treatment alone or in combination for 24 h or 12 h. The THP-1 cells were divided into the following experimental groups: (1) blank control group; (2) artesunate group (0.8 μM); (3) venetoclax group (0.1 μM); (4) cytarabine group (8 μM); (5) artesunate (0.8 μM) + venetoclax (0.1 μM) group; (6) artesunate (0.8 μM) + cytarabine (8 μM) group; (7) venetoclax (0.1 μM) + cytarabine (8 μM) group; (8) artesunate (0.8 μM) + venetoclax (0.1 μM) + cytarabine (8 μM) group. The MOLM-13 cell experimental groups were as follows: (1) blank control group; (2) artesunate group (0.2 μM); (3) venetoclax group (0.01 μM); (4) cytarabine group (0.08 μM); (5) artesunate (0.2 μM) + venetoclax (0.01 μM) group; (6) artesunate (0.2 μM) + cytarabine (0.08 μM) group; (7) venetoclax (0.01 μM) + cytarabine (0.08 μM) group; (8) artesunate (0.2 μM) + venetoclax (0.01 μM) + cytarabine (0.08 μM) group. Western-blot technology was used to study the mechanism of the combination of artesunate + venetoclax + cytarabine. Apoptosis-related proteins, DNA damage proteins and replication stress checkpoint kinases were investigated in THP-1 and MOLM-13 cells (see Figure 7 ).

[0097] The experimental results are shown in the figure. The artesunate-based combination regimen induced the upregulation of Noxa. Noxa can indirectly inhibit Mcl-1 by binding to Mcl-1. However, the upregulation of Noxa alone is not sufficient to induce cell apoptosis and DNA damage, and Bcl-2 must be inhibited at the same time. The combination of venetoclax and artesunate can synergistically induce the cleavage of PARP and caspase-3 and the upregulation of γ-H2A.X, which was further increased in the artesunate + venetoclax + cytarabine group, accompanied by Mcl-1 downregulation. Cytarabine is the cornerstone of AML treatment. Cytarabine can be incorporated into DNA, inhibit DNA synthesis, cause cell cycle arrest and induce DNA damage to exert anti-tumor effects. However, cytarabine treatment will also induce phosphorylation activation of replication stress checkpoint kinase Chk, initiate the DNA damage repair process, and then the cytarabine-based combination regimen induces upregulation of p-Chk1. Artesunate and venetoclax combined induce caspase-dependent Mcl-1 downregulation, thereby overcoming the cytarabine-induced p-Chk1 upregulation. Compared with the cytarabine group, artesunate + cytarabine group and venetoclax + cytarabine group, the artesunate + venetoclax + cytarabine group had lower p-Chk1 and Mcl-1 levels. The above results confirmed that artesunate enhanced the apoptosis-inducing effect of venetoclax by inducing Noxa upregulation, while reducing the protein level of Mcl-1, thereby overcoming the activation of p-Chk1 induced by cytarabine and enhancing the DNA damage effect of cytarabine.

[0098] The basic anti-apoptotic protein expression levels of THP-1 and MOLM-13 cells of the present invention are different. MOLM-13 cells highly express Bcl-2 while lowly express Mcl-1 and Bim, and are sensitive to venetoclax and cytarabine; THP-1 cells highly express Bcl-2, Mcl-1 and Bim, and are relatively tolerant to venetoclax and cytarabine. Therefore, the present invention selects different concentrations of artesunate, venetoclax and cytarabine to treat the two cells, and it is found in both cells that the combination of the three drugs produces a stronger killing effect on AML cells than the combination of any two drugs.

[0099] In summary, compared with artesunate, venetoclax, cytarabine or any combination of two drugs alone, artesunate not only induces Noxa and cooperates with venetoclax to induce apoptosis, but also downregulates the protein level of Mcl-1 to overcome the p-Chk1 resistance mechanism of cytarabine, so that the three-drug combination produces a stronger synergistic killing effect on AML cells than the combination of any two drugs.

Claims

1. A composition containing artemisinin derivatives, characterized in that: The composition comprises component A, component B and component C mixed in a ratio of 8-40:1-2:1-80; wherein the component A is artesunate; the component B is venetoclax; and the component C is cytarabine.

2. Use of a composition containing artemisinin derivatives according to claim 1, characterized in that: Use of the composition in preparing a drug for treating acute myeloid leukemia; The acute myeloid leukemia cells are THP-1 or MOLM-13 cells.

3. The use of the composition containing artemisinin derivatives according to claim 2, characterized in that: The composition is used in preparing a drug for treating acute myeloid leukemia by inducing Noxa to reduce Mcl-1, thereby synergistically inducing leukemia cell apoptosis and enhancing DNA damage.

4. A preparation of a composition containing artemisinin derivatives according to claim 1, characterized in that: The active ingredient of the preparation is mixed with a pharmaceutically acceptable carrier, wherein the active ingredient is the composition according to claim 1, and the active ingredient accounts for 0.01-99% of the mass of the preparation.

5. The preparation of the composition containing artemisinin derivatives according to claim 4, characterized in that: The dosage form of the preparation is tablet, capsule or granule.

6. The preparation of the composition containing artemisinin derivatives according to claim 5, characterized in that The preparation is prepared by mixing the components in the composition and then mixing them with a pharmaceutically acceptable carrier, or by separately preparing the components in the composition with a pharmaceutically acceptable carrier and then mixing them.

Citation Information

Patent Citations

  • Application of ART (artesunate) as anti-leukemia-tumor drug

    CN107050014A

  • Silanol based therapeutic payloads

    CN109475567A

  • Application of Hsp90 inhibitor 17-DMAG in preparation of drugs for inhibiting puerile acute lymphoblastic leukemia

    CN110151775A

  • Treatment of leukemia with artemisinin derivatives and combinations with other antineoplastic agents

    US20160175331A1

  • Dosage forms and use thereof

    US20160354315A1